Linfoma não-Hodgkin indolente de células B é um câncer de crescimento lento que afeta linfócitos B. Pode causar infecções recorrentes, sangramento gastrointestinal, problemas respiratórios e outros sintomas devido ao acúmulo de células doentes.
Introdução
O que você precisa saber de cara
Visão geral
O linfoma não-Hodgkin indolente de células B (em inglês: Indolent B-cell non-Hodgkin lymphoma) é uma condição hematológica categorizada como MONDO:0017594. Os dados clínicos indicam que o início dos sinais e manifestações costuma ocorrer na idade adulta (Adult), com prevalência atualmente desconhecida.[1][2]
Sinais e sintomas
As manifestações clínicas relatadas incluem linfoma, hepatomegalia, palidez, anorexia, edema pedal, edema periorbital e proptose. Há também descrições de alterações respiratórias e vasculares, tais como insuficiência respiratória, epistaxe, hemorragia gastrointestinal, vasculite, crioglobulinemia, hipercoagulabilidade e morfologia vascular retiniana anormal.[1][2]
No âmbito neurológico e sistêmico, foram identificados enxaqueca, neuropatia periférica, polineuropatia, paralisia de nervo craniano, comprometimento da memória, nível de consciência ou confusão reduzida e acidente vascular cerebral. Alterações laboratoriais e imunológicas associadas compreendem infecções recorrentes, hipercalcemia, aumento da concentração circulante de lactato desidrogenase e taxa de sedimentação de eritrócitos elevada.[1][2]
Causas genéticas
Diversos genes estão associados à base molecular e regulação celular da doença: MYD88 (Myeloid differentiation primary response protein MyD88), MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), BIRC3 (Baculoviral IAP repeat-containing protein 3), FOXP1 (Forkhead box protein P1), ARL11 (ADP-ribosylation factor-like protein 11), IKZF3 (Zinc finger protein Aiolos), RPS15 (Small ribosomal subunit protein uS19), IGHV4-34 (Immunoglobulin heavy variable 4-34), IGHG1 (Immunoglobulin heavy constant gamma 1), BCL2 (Apoptosis regulator Bcl-2), CCND1 (G1/S-specific cyclin-D1) e HLA-DRB1 (HLA class II histocompatibility antigen, DRB1 beta chain).[1][3]
Diagnóstico
Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.
O linfoma não-Hodgkin indolente de células B é um grupo de tumores do sangue com crescimento lento, que costuma ter início na fase adulta. A doença pode causar palidez, cansaço, infecções frequentes, sangramentos nasais e inchaço nos membros ou ao redor dos olhos. No Brasil, o medicamento VENCLEXTA tem registro na ANVISA, embora a condição não esteja incluída na lista de PCDTs do SUS para doenças raras. Existem pesquisas clínicas ativas, com centros no Brasil investigando novos tratamentos para melhorar o cuidado dos pacientes.
Linfoma não-Hodgkin indolente de células B é um câncer de crescimento lento que afeta linfócitos B. Pode causar infecções recorrentes, sangramento gastrointestinal, problemas respiratórios e outros sintomas devido ao acúmulo de células doentes.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 30 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 73 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
21 genes identificados com associação a esta condição.
Immunodeficiency 68
An autosomal recessive primary immunodeficiency characterized by life-threatening, often recurrent, pyogenic bacterial infections, including invasive pneumococcal disease, beginning in infancy or early childhood.
Immunodeficiency 12
A primary immunodeficiency characterized by onset in infancy of recurrent bacterial and candidal infections resulting in bronchiectasis and growth delay. Manifestations include mastoiditis, aphthous ulcers, cheilitis, gingivitis, esophagitis, gastritis, duodenitis, and meningitis. Levels of absolute lymphocytes and serum immunoglobulins are normal, but specific antibody titers are low despite immunization, and T-cells show impaired proliferative responses to mitogens.
Leukemia, chronic lymphocytic
A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.
Immunodeficiency 84
An autosomal recessive immunologic disorder characterized by recurrent sinopulmonary infections from childhood associated with low levels of B cells and impaired early B-cell development. There may also be variable T-cell abnormalities. Patients have increased susceptibility to infection with Epstein-Barr virus and a propensity for the development of lymphoma in adulthood.
Multiple myeloma
A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.
Tumor predisposition syndrome 3
An autosomal dominant disorder characterized by an increased risk for the development of various types of benign and malignant neoplasms throughout life, with age-dependent penetrance. Affected individuals can develop neoplasms involving epithelial, mesenchymal, and neuronal tissues, as well as lymphoid and myeloid cancers. The disorder is associated with elongated telomeres.
Ataxia telangiectasia
A rare recessive disorder characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. Patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.
Medicamentos e terapias
Mecanismo: DNA polymerase (alpha/delta/epsilon) inhibitor
Mecanismo: B-lymphocyte antigen CD20 binding agent
Mecanismo: B-lymphocyte antigen CD20 binding agent
Mecanismo: PI3-kinase p110-delta subunit inhibitor
Mecanismo: Apoptosis regulator Bcl-2 inhibitor
Mecanismo: Tyrosine-protein kinase BTK inhibitor
Mecanismo: Tyrosine-protein kinase BTK inhibitor
Mecanismo: PI3-kinase p110-gamma subunit inhibitor
Variantes genéticas (ClinVar)
156 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
196 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Linfoma não-Hodgkin indolente de células B
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 6 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
10 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
23 ensaios clínicos encontrados, 15 ativos.
Publicações mais relevantes
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.
A Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response.
Background and Clinical Significance: Waldenström macroglobulinemia (WM) is a rare, indolent B-cell non-Hodgkin lymphoma, characterised by the presence of monoclonal immunoglobulin M (IgM) and lymphoplasmacytic infiltration of the bone marrow. It is often associated with various haematological and systemic disorders, including previous cold agglutinin disease (CAD), a condition where cold-sensitive antibodies lead to haemolysis. Case Presentation: A 55-year-old male patient was admitted to the Internal Diseases Ward with symptoms of weakness, reduced effort tolerance, and weight loss, along with life-threatening normoblastic anaemia (haemoglobin [Hb]: 3.90 g/dL). Initial blood tests raised suspicion of CAD due to the presence of multiple blood clots, as well as a decrease in lymphocyte and neutrophil counts. CAD was then confirmed by a cold agglutinin titre of 1:2000 and direct antiglobulin test ([DAT] 4+). Two weeks later, upon transfer to the Haematological Diseases Ward, further investigation revealed elevated IgM levels (up to 31.55 g/L). Additional diagnostic tests, including serum protein electrophoresis, imaging, multiparametric flow cytometry, and bone marrow biopsy, confirmed the diagnosis of WM. The L265P MYD88 mutation test was positive. Treatment with intravenous rituximab was initiated, followed by bendamustine/rituximab (BR) therapy protocol as first-line treatment. After two cycles, the patient's clinical condition and laboratory results significantly improved, with a marked reduction in IgM (<0.4 g/L). Hb levels steadily rose to 12.60 g/dL, eliminating the need for further blood transfusions. Conclusions: This case highlights the importance of recognising the coexistence of CAD and WM, which may present with overlapping clinical features, including life-threatening anaemia. Extensive diagnostics and prompt treatment with combination therapy can lead to effective clinical improvement.
[Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study].
Objective: To investigate the efficacy and safety of bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma (B-iNHL) . Methods: The clinical data of 159 patients with B-iNHL enrolled in 16 hospitals from Jiangsu Cooperative Lymphoma Group from December 1, 2019, to April 20, 2024, were analyzed for regimen efficacy and safety. Bendamustine plus rituximab (BR) and bendamustine plus obinutuzumab (BG) were administered to 139 (87.4% ) and 20 (12.6% ) patients, respectively. Results: Among the 159 patients, 101 (63.5% ) were male and 58 (36.5% ) were female, with a median age of 69 years (range: 60-84). Efficacy could be assessed in 138 (86.8% ) patients. The efficacy assessment demonstrated that the overall response rate was 92.0% with complete and partial remissions in 75 (54.3% ) and 52 (37.7% ) cases, respectively. With a median follow-up of 24 months (range: 4-64), the progression-free survival rate was (87.5 ± 3.0) % and the overall survival rate was (83.2 ± 3.3) %. Of the 27 patients who died, 6 (22.2% ) died due to disease progression. The mean applied dose of bendamustine per cycle was 73.0 (50.8-89.7) mg/m(2) per day, administered on days 1 and 2. Adverse events of grade 3 or higher were reported in 53 (33.3% ) patients, with infection (30 cases,18.9% ) and neutropenia (24 cases, 15.1% ) demonstrating the highest incidence. Conclusion: Bendamustine combined with anti-CD20 monoclonal antibody demonstrated good efficacy and is well-tolerated in the first-line treatment of elderly patients with B-iNHL. 目的： 评估苯达莫司汀联合抗CD20单抗一线治疗老年惰性B细胞非霍奇金淋巴瘤（B-iNHL）患者的疗效与安全性。 方法： 回顾性分析2019年12月1日至2024年4月20日期间在江苏省淋巴瘤协作组16家医院就诊的159例老年B-iNHL患者应用苯达莫司汀联合抗CD20单抗（利妥昔单抗或奥妥珠单抗）治疗的疗效及安全性。其中139例（87.4%）应用BR（苯达莫司汀+利妥昔单抗）方案治疗，20例（12.6%）应用BG（苯达莫司汀+奥妥珠单抗）方案治疗。 结果： 159例患者中男101例（63.5%）、女58例（36.5%），中位年龄为69（60~84）岁。138例（86.8%）患者可评估疗效，其中75例（54.3%）患者达完全缓解，52例（37.7%）患者达部分缓解，总有效率为92.0%。中位随访24（4~64）个月，患者无进展生存率为（87.5±3.0）%，总生存率为（83.2±3.3）%。死亡的27例患者中，仅6例（22.2%）伴有疾病进展。每周期苯达莫司汀中位应用剂量为73.0（50.8~89.7）mg·m(-2)·d(-1)，第1、2天用药。53例（33.3%）患者出现3级及以上的不良反应，感染（30例，18.9%）发生率最高，其次是中性粒细胞减少（24例，15.1%）。 结论： 真实世界老年B-iNHL患者一线应用苯达莫司汀联合抗CD20单抗疗效较好，安全性可控，耐受性较好。.
The emerging role of tafasitamab in follicular lymphoma.
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma, characterized by recurrent relapses, risk of histologic transformation, and heterogeneous clinical outcomes. Despite advances with novel therapies, the management of relapsed/refractory FL remains challenging. Tafasitamab, a humanized anti-CD19 monoclonal antibody, is currently approved, in combination with lenalidomide, for relapsed refractory (R/R) diffuse large B-cell lymphoma (DLBCL), and together with lenalidomide and rituximab for R/R FL. Clinical trial data support its efficacy and manageable safety profile in FL starting from fisrt relapse, including in high-risk FL subgroups such as early relapse (POD24) and CD20-refractory disease. This chemotherapy-free regiment is added with its favorable safety profile to more complex therapies such as CAR T-cell therapy or bispecific antibodies. Further studies are needed to clarify tafasitamab's durability of benefit, optimal sequencing, and integration within the evolving FL treatment landscape.
Splenic marginal zone lymphoma associated with chronic inflammatory demyelinating polyradiculoneuropathy: a case report.
Chronic inflammatory demyelinating polyradiculopathy (CIDP) is an acquired immune-mediated neuropathy characterized by progressive or relapsing-remitting proximal and distal weakness. Lymphomas are among various hematological malignancies associated with CIDP. Splenic marginal zone lymphoma (SMZL) is a rare, indolent B-cell non-Hodgkin lymphoma that classically presents with splenomegaly and cytopenia. The co-occurrence of SMZL and CIDP is extremely rare; the diagnosis thus presents a unique challenge both diagnostically and therapeutically. We report a 65-year-old male patient with progressive proximal weakness, night sweats, and splenomegaly. Investigations revealed pancytopenia with imaging studies confirming the splenomegaly. Further investigations, such as a bone marrow biopsy and histopathology of the spleen, were indicative of a hypocellular marrow and SMZL, respectively. Simultaneously, a diagnosis of CIDP was established based on clinical findings, as well as electromyography and nerve conduction studies. For CIDP, immunosuppressive therapy was initiated; however, no treatment was administered for SMZL due to its indolent nature. He showed partial neurological improvement with the treatment given for CIDP. This underlines the importance of treating both diseases. The rare association of CIDP and SMZL is presented in this case, highlighting the importance of a comprehensive diagnostic workup in patients with neurological and hematological abnormalities. Therefore, for the management of such patients, timely identification and appropriate therapeutic approaches will be necessary for an improved outcome.
Publicações recentes
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.
A Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response.
[Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study].
The emerging role of tafasitamab in follicular lymphoma.
Splenic marginal zone lymphoma associated with chronic inflammatory demyelinating polyradiculoneuropathy: a case report.
📚 EuropePMC35 artigos no totalmostrando 61
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.
British journal of haematologyA Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response.
Diagnostics (Basel, Switzerland)[Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiThe emerging role of tafasitamab in follicular lymphoma.
Leukemia & lymphomaSplenic marginal zone lymphoma associated with chronic inflammatory demyelinating polyradiculoneuropathy: a case report.
Journal of medicine and lifeIdentifying high-risk patients with MALT lymphoma undergoing first-line therapy for disease progression.
Expert review of hematologyLong-acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine-treated patients with indolent B cell non-Hodgkin lymphoma: a multicentric real-life experience.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerChimeric antigen receptor T-cell therapy in aggressive lymphomas.
Current opinion in oncologyNodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment.
Hematological oncology[Modern systemic treatment-bispecific antibodies and CAR-T cell therapy : Clinical management, mechanisms of action, outcomes].
Radiologie (Heidelberg, Germany)Outcomes of the transformation to diffuse large B-cell lymphoma in hodgkin lymphoma and indolent B-cell non-Hodgkin lymphoma: a population-based study.
Annals of hematologyAn Autopsy Case of Bronchiolitis Obliterans Associated With Oral Lichen Planus and Non-Hodgkin Lymphoma.
CureusConcurrent papillary thyroid carcinoma and incidental cervical lymph node indolent B cell non-Hodgkin lymphoma: clinicopathological features, outcomes, and potential relationships.
World journal of surgical oncologyAdvances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.
Current treatment options in oncologySafety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.
EClinicalMedicineClinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.
Transplantation and cellular therapyPost-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database.
Frontiers in pharmacologyPrognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.
Hematological oncologyLenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
Leukemia & lymphomaTreatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
Cancers[Expert Consensus on the prevention and treatment of indolent B-cell non-Hodgkin lymphoma with novel coronavirus infection].
Zhonghua yi xue za zhi[Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiBendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
CancerEfficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.
Blood advancesPhase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.
Clinical pharmacology in drug developmentA phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan.
Cancer chemotherapy and pharmacologyBendamustine: A review of pharmacology, clinical use and immunological effects (Review).
Oncology reportsEvolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.
Journal of hematology & oncologyBendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study.
Chinese medical journalHistologic Transformation in an Untreated Waldenstrom's Macroglobulinemia After 14 Years: Case Report and Review of the Literature.
Journal of hematologyPhase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Japanese journal of clinical oncologyA phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.
Blood advancesRepeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.
Cancer medicineHigh-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result.
European journal of haematologyWhere does transplant fit in the age of targeted therapies?
Hematology. American Society of Hematology. Education ProgramDisseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets.
BMC infectious diseasesCombined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
International journal of hematologyMALT Lymphoma as a Model of Chronic Inflammation-Induced Gastric Tumor Development.
Current topics in microbiology and immunologySafety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
JCI insightThe HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Molecular carcinogenesisBurden of illness of follicular lymphoma and marginal zone lymphoma.
Annals of hematologyT follicular helper cells: a potential therapeutic target in follicular lymphoma.
OncotargetA Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
Clinical lymphoma, myeloma & leukemiaSafety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation.
Journal of clinical pharmacologyBendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
International journal of hematologyB-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.
The American journal of pathologyJapanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
International journal of hematologyThe discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Expert opinion on drug discoveryRed Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
Journal of nuclear medicine : official publication, Society of Nuclear MedicinePhase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
British journal of haematologyA phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
British journal of haematologyDulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.
The Lancet. HaematologyWhole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.
BMC cancerRituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation.
Current opinion in hematologyRandomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyEmerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Expert review of anticancer therapyProgression and Transformation of Clonally Heterogeneous B-cell Lymphoma.
PloS oneEffect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
Cancer chemotherapy and pharmacologyAdvancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.
Future oncology (London, England)A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
International journal of hematologyA phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
HaematologicaAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Linfoma não-Hodgkin indolente de células B.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Linfoma não-Hodgkin indolente de células B e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
Por se tratar de uma categoria de neoplasia linfoide indolente, apresenta evolução tipicamente crônica e de desenvolvimento lento. Estudos clínicos continuam investigando tratamentos direcionados para controlar a proliferação celular e a progressão da doença.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
4 fontes citadas no texto · 5 publicações do grafo RarasNet (PubMed) · 5 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (2026). Linfoma não-Hodgkin indolente de células B. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/linfoma-nao-hodgkin-indolente-de-celulas-b
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Linfoma não-Hodgkin indolente de células B
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- NIH/GARD
- fonte: GARD (NIH)
- Dado público estruturado
- fonte: Wikidata
- Moléculas estudadas na doença
- fonte: OpenTargets
- Ensaios clínicos
- fonte: ClinicalTrials.gov
